ArticleBMC biotechnology2026
A novel method to encapsulate polydeoxyribonucleotides extracted from trout into exosomes and applications in skin recovery.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polydeoxyribonucleotide (PDRN), a DNA polymer derived from salmonid tissue, is widely used in regenerative dermatology but its topical application is limited by poor stability and delivery efficiency. Exosomes, nanoscale vesicles with high cellular uptake and low immunogenicity, offer a promising platform for nucleic acid protection and targeted delivery. In this study, we developed an electroporation-based method to load fragmented PDRN into HaCaT-derived exosomes for enhanced skin regeneration. PDRN was extracted, ultrasonically fragmented to < 200 bp, and encapsulated into exosomes using optimized electroporation parameters. Exosome integrity and size distribution were confirmed by nanoparticle tracking analysis and transmission electron microscopy. Functional activity was evaluated using wound-healing scratch assays and RT-qPCR of pro-inflammatory (TNF-α, IL-6, IL-1β) and regeneration-associated (COL1A1, MMP2) genes. PDRN-loaded exosomes significantly accelerated wound closure and exhibited superior anti-inflammatory effects compared with exosome-only and PDRN-only controls in a dose- and time-dependent manner. Pro-inflammatory cytokine mRNA levels were markedly reduced, while COL1A1 and MMP2 expression were significantly increased at 200 ng, indicating activation of extracellular matrix remodeling pathways. These findings demonstrate that exosome-encapsulated PDRN delivery via electroporation enhances DNA stability and regenerative efficacy without compromising vesicle structure, highlighting its potential as an advanced cosmetic and therapeutic platform for skin repair. Therefore, clinical trials are needed to develop cosmetics or therapeutics using exosome-encapsulated PDRN in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.